Organisation paid for research Program year 2025 Source: CMS Open Payments

Cleveland Clinic

Neither a doctor nor a teaching hospital

Research payments

$8,563,323

322 payments

Through program year 2025, Cleveland Clinic is reported as receiving $8,563,323 in research payments, across 322 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $775,930 53
2024 Research $903,688 62
2023 Research $2,713,726 54
2022 Research $1,451,948 36
2021 Research $1,203,647 23
2020 Research $1,107,554 70
2019 Research $406,829 24

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $2,121,313 11 payments
  2. E.R. Squibb & Sons, L.L.C. $1,202,582 21 payments
  3. Jazz Pharmaceuticals Inc. $849,000 4 payments
  4. Boston Scientific Corporation $760,733 40 payments
  5. Pfizer Inc. $475,493 13 payments
  6. Organon LLC $452,027 2 payments
  7. Allergan Inc. $302,416 1 payment
  8. Medtronic, Inc. $277,650 37 payments
  9. Alcon Research LLC $249,162 3 payments
  10. Alnylam Pharmaceuticals Inc. $194,920 12 payments
Studies the money was for Research payments · program years 2019–2025
  1. An Open-Label, Randomized, Phase III Study Comparing 177Lu-Psma-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (Mhspc) $2,092,633 6 payments
  2. Abatacept CTLA4-Ig for the Treatment of Relapsing Non Severe Granulomatosis with Polyangiitis Wegeners ABROGATE $949,211 2 payments
  3. Lower Doses of Cpx-351 for the Treatment of Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes $849,000 4 payments
  4. Watch Tavr $500,000 1 payment
  5. Developing and testing an implementation toolkit to make long acting reversible contraceptives (LARCs) a reality in pediatric practices $452,027 2 payments
  6. Prospective Randomized Comparative Trial for Combination Dexamethasone Implant With PRN Anti-Vegf Therapy to Anti-Vegf Therapy Alone in Treatment Resistant Diabetic MacUlar Edema: Informing the Role for Imaging Biomarkers and Combination Therapy $302,416 1 payment
  7. INVOS CathLab $270,183 33 payments
  8. Nivolumab Plus Talazoparib in Unresectable and Metastatic Melanoma $244,944 2 payments
  9. Expanded Access Protocol to Provide Patisiran to Patients With Transthyretin-mediated Amyloidosis (ATTR Amyloidosis) With Cardiomyopathy $194,920 12 payments
  10. A Phase 1B Openlabel Dosefinding Study to Evaluate Safety Pharmacokinetics and Pharmacodynamics of Avelumab Msb0010718c in Combination With Axitinib AG013736 in Patients With Previously Untreated Advanced Renal Cell Cancer $158,366 1 payment
What the money was spent on Research payments · program years 2019–2025
  1. Patient care $452,050 3 payments
  2. Other $97 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record